Table 1. The Netherlands Cancer Institute EAP experience – patient demography (Haringhuizen et al, 2003).
| Patients, n, evaluable/nonevaluable | 92/8 |
| Male/female, n | 48/44 |
| WHO/ECOG performance statusa 0/1/2/3/4 | 9/37/22/7/1 |
| Histology (%) | |
| Adenocarcinoma | 51 |
| Squamous-cell carcinoma | 20 |
| Large-cell carcinoma | 15 |
| Bronchioalveolar carcinoma | 6 |
| Stage III/IV | 13/79 |
| Previous chemotherapy, n | |
| Chemonaive | 7 |
| First line | 57 |
| Second line | 19 |
| Third line | 7 |
| Fourth line | 2 |
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group.
a
Not recorded in 16 patients.